Compare Abeona Therapeutics Inc (ABEO) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bank of New York Mellon Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Bank of New York Mellon Corp trades at $162.9 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 258.3× Abeona Therapeutics Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BNY | |
|---|---|---|
Market Cap | $421.19M | $108.78B |
Sector | Health | Financials |
52-Week High | $7.45 | $162.35 |
52-Week Low | $4.17 | $101.00 |
Enterprise Value | $276.10M | — |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
BNY stock trades at $162.98, up 2.22% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported record Q2 2026 results with EPS of $2.46, surpassing estimates, and announced a strategic collaboration to advance digital asset infrastructure. Revenue growth is steady, rising to $19.76B in 2025, with a net income margin of 29.96%.
Outlook remains positive with a consensus price target of $170.36, though risks include high investing cash outflows and competitive pressures. The stock's current price is near the consensus target, suggesting limited upside without further catalysts. Institutional sentiment is mixed, with 45% buy ratings and 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
